Update of the Ascend-CML Study of Frontline Asciminib: High Rate of Optimal Response and Resistance Due to Mutations Is Rare
David T Yeung(Royal Adelaide Hospital), Timothy P. Hughes(Royal Adelaide Hospital), Rosemary Harrup(University of Tasmania), Naranie Shanmuganathan(South Australia Pathology), Carolyn Grove(The University of Western Australia), David M. Ross(Flinders Medical Centre), Cecily Forsyth(Gosford Hospital), John Reynolds(The Alfred Hospital), Jake Shortt(The University of Melbourne), Lynette Chee(The Royal Melbourne Hospital), Steven Lane(QIMR Berghofer Medical Research Institute), Agnes S. M. Yong(South Australia Pathology), Andrew Grigg(The Royal Melbourne Hospital), Mannu Walia(St Vincents Institute of Medical Research), Ilona Cunningham(The University of Sydney), Alwyn D’Souza(Wellington Hospital), Peter Browett(University of Auckland), Matthew P.F. Wright(Fiona Stanley Hospital), Robin Filshie(St Vincent's Hospital Melbourne), Nicholas Vialla(Liverpool Hospital), Susan Branford(South Australia Pathology)
Cited by 6
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464